|
1
|
Koperek O, Kornauth C, Capper D, Berghoff
AS, Asari R, Niederle B, von Deimling A, Birner P and Preusser M:
Immunohistochemical detection of the BRAF V600E-mutated protein in
papillary thyroid carcinoma. Am J Surg Pathol. 36:844–850. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X,
et al: Papillary microcarcinoma of the thyroid: Clinical
characteristics and BRAF (V600E) mutational status of 977 cases.
Ann Surg Oncol. 20:2266–2273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balta AZ, Filiz AI, Kurt Y, Sucullu I,
Yucel E and Akin ML: Prognostic value of oncoprotein expressions in
thyroid papillary carcinoma. Med Oncol. 29:734–741. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morita N, Ikeda Y and Takami H: Clinical
significance of p53 protein expression in papillary thyroid
carcinoma. World J Surg. 32:2617–2622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zafon C, Obiols G, Castellvi J, Tallada N,
Baena JA, Simo R, et al: Clinical significance of RET/PTC and p53
protein expression in sporadic papillary thyroid carcinoma.
Histopathology. 50:225–231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hamzany Y, Soudry E, Strenov Y, Lipschitz
N, Segal K, Hadar T, et al: Early death from papillary thyroid
carcinoma. Am J Otolaryngol. 33:104–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horie S, Maeta H, Endo K, Ueta T,
Takashima K and Terada T: Overexpression of p53 protein and MDM2 in
papillary carcinomas of the thyroid: Correlations with
clinicopathologic features. Pathol Int. 51:11–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parameswaran R, Brooks S and Sadler GP:
Molecular pathogenesis of follicular cell derived thyroid cancers.
Int J Surg. 8:186–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SJ, Lee KE, Myong JP, Park JH, Jeon
YK, Min HS, et al: BRAF V600E mutation is associated with tumor
aggressiveness in papillary thyroid cancer. World J Surg.
36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim KH, Kang DW, Kim SH, Seong IO and Kang
DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a
Korean population. Yonsei Med J. 45:818–821. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Musholt TJ, Schonefeld S, Schwarz CH,
Watzka FM, Musholt PB, Fottner C, et al: Impact of pathognomonic
genetic alterations on the prognosis of papillary thyroid
carcinoma. ESES vienna presentation. Langenbecks Arch Surg.
395:877–883. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahn D, Park JS, Sohn JH, Kim JH, Park SK,
Seo AN and Park JY: BRAF (V600E) mutation does not serve as a
prognostic factor in Korean patients with papillary thyroid
carcinoma. Auris Nasus Larynx. 39:198–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ricarte-Filho J, Ganly I, Rivera M, Katabi
N, Fu W, Shaha A, et al: Papillary thyroid carcinomas with cervical
lymph node metastases can be stratified into clinically relevant
prognostic categories using oncogenic BRAF, the number of nodal
metastases and extra-nodal extension. Thyroid. 22:575–584. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurt B, Yalcin S, Alagoz E, Karslıoğlu Y,
Yigit N, Gunal A, et al: The relationship of the BRAF (V600E)
Mutation and the established prognostic factors in papillary
thyroid carcinomas. Endocr Pathol. 23:135–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prescott JD, Sadow PM, Hodin RA, Le LP,
Gaz RD, Randolph GW, et al: BRAF V600E status adds incremental
value to current risk classification systems in predicting
papillary thyroid carcinoma recurrence. Surgery. 152:984–990. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elisei R, Viola D, Torregrossa L, Giannini
R, Romei C, Ugolini C, et al: The BRAF (V600E) mutation is an
independent, poor prognostic factor for the outcome of patients
with low-risk intrathyroid papillary thyroid carcinoma:
single-institution results from a large cohort study. J Clin
Endocrinol Metab. 97:4390–4398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Daglar-Aday A, Toptas B, Ozturk T, Seyhan
F, Saygili N, Eronat A, et al: Investigation of BRAF V600E mutation
in papillary thyroid carcinoma and tumor-surrounding nontumoral
tissues. DNA Cell Biol. 32:13–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong D, Jeong Y, Park JH, Han SW, Kim SY,
Kim YJ, et al: BRAF (V600E) mutation analysis in papillary thyroid
carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg
Oncol. 20:759–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brahma B, Yulian ED, Ramli M, Setianingsih
I, Gautama W, Brahma P, et al: Surgical perspective of T1799A BRAF
mutation diagnostic value in papillary thyroid carcinoma. Asian Pac
J Cancer Prev. 14:31–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, et al: Association between BRAF V600E
mutation and mortality in patients with papillary thyroid cancer.
JAMA. 309:1493–1501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gauchotte G, Philippe C, Lacomme S,
Leotard B, Wissler MP, Allou L, et al: BRAF, p53 and SOX2 in
anaplastic thyroid carcinoma: evidence for multistep
carcinogenesis. Pathology. 43:447–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park KY, Koh JM, Kim YI, Park HJ, Gong G,
Hong SJ, et al: Prevalences of Gs alpha, ras, p53 mutations and
ret/PTC rearrangement in differentiated thyroid tumours in a Korean
population. Clin Endocrinol (Oxf). 49:317–323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu MC and Gelmann EP: P53 gene mutations:
case study of a clinical marker for solid tumors. Semin Oncol.
29:246–257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Omar E, Madhavan M and Othman NH:
Immunohistochemical localisation of RET and p53 mutant protein of
thyroid lesions in a North-Eastern Malaysian population and its
prognostic implications. Pathology. 36:152–159. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dellis RA, Lloyd RV, Heitz U and Eng C:
Tumours of endocrine organsPathology and Genetics. International
Agency for Research on Cancer Press; Lyon: pp. 57–66. 2004
|
|
26
|
Mitzner R: Neck Dissection Classification.
http://emedicine.medscape.com/article/849834-overviewJune
9th–2015
|
|
27
|
Witt RL, Ferris RL, Pribitkin EA, Sherman
SI, Steward DL and Nikiforov YE: Diagnosis and management of
differentiated thyroid cancer using molecular biology.
Laryngoscope. 123:1059–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Min HS, Lee C and Jung KC: Correlation of
immunohistochemical markers and BRAF mutation status with
histological variants of papillary thyroid carcinoma in the Korean
population. J Korean Med Sci. 28:534–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smith RA, Salajegheh A, Weinstein S,
Nassiri M and Lam AK: Correlation between BRAF mutation and the
clinicopathological parameters in papillary thyroid carcinoma with
particular reference to follicular variant. Hum Pathol. 42:500–506.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cvejic D, Selemetjev S, Savin S, Paunovic
I, Petrovic I and Tatic S: Apoptosis and proliferation related
molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma
versus papillary carcinoma of the thyroid. Pathology. 40:475–480.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karlidag T, Cobanoglu B, Keles E, Alpay
HC, Ozercan I, Kaygusuz I, et al: Expression of Bax, p53 and
p27/kip in patients with papillary thyroid carcinoma with or
without cervical nodal metastasis. Am J Otolaryngol. 28:31–36.
2007. View Article : Google Scholar : PubMed/NCBI
|
